Morgan Stanley raised the firm’s price target on Biogen to $371 from $349 and keeps an Overweight rating on the shares after the company reported Q1 results. The firm derives its price target from a discounted cash flow analysis using a 10% discount rate and 2% terminal growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
- Biogen confirms FDA grants accelerated approval for Qalsody
- FDA approves Biogen’s Qalsody for ALS patients with SOD1 gene mutation
- Cantor thinks M&A premium ‘baked into’ TG Therapeutics shares will increase
- Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48